Pivekimab is a human IgG1 monoclonal antibody targeting interleukin 3 (IL-3) and CD123. Pivekimab can be used in the study of blastocytic plasmacytoid dendritic cell tumor (BPDCN)[1].
[1]. Patrick ZM, et, al. Methods of treatment using anti-CD123 immunoconjugates. WO2020092533.
















